ArticleNeuropsychopharmacology reports2025
Sleep Architecture Alterations Following High-Dose Steroid Pulse Therapy: A Pilot Study Using a Portable Electroencephalogram-Based Device.
Article in Neuropsychopharmacology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dexamethasone induces sleep disruption in male mice and is associated with hyperactivation of orexin neurons.Psychopharmacology · 2026Article
- Sleep Architecture Alterations Following High-Dose Steroid Pulse Therapy: A Pilot Study Using a Portable Electroencephalogram-Based Device.Neuropsychopharmacology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSleep disturbance is a common side effect of high-dose steroid pulse therapy (SPT). However, in clinical settings, the impact of this therapy on sleep architecture has not been objectively studied.
objectiveThis study aimed to investigate changes in sleep architecture associated with high-dose SPT administration in patients with neuroimmunological disorders.
methodsA prospective cohort study was conducted involving six hospitalized patients with neuroimmunological disorders who were administered intravenous methylprednisolone (1000 mg/day for 3 days). Objective sleep parameters were assessed on days 0, 1, and 3 using a SleepGraph, a validated portable electroencephalography (EEG) device. Subjective sleep was evaluated using the Insomnia Severity Index (ISI), Pittsburgh Sleep Quality Index (PSQI), sleep diary, and Likert scale.
resultsRapid eye movement (REM) sleep significantly decreased from 71.2 ± 36.6 min on day 0 to 9.4 ± 8.3 min on day 1 and remained low on day 3 (16.5 ± 16.0 min). Total sleep time was also reduced, while non-REM (NREM) sleep remained relatively stable. Two patients who received lemborexant showed partial improvement in their sleep parameters. ISI and PSQI scores did not change significantly, possibly owing to the short observation period.
conclusionThese findings suggest that high-dose SPT can markedly reduce REM sleep. Moreover, portable EEG devices could be a practical approach for monitoring steroid-induced sleep alterations. Our findings provide clinical evidence that may help to deepen the objective understanding of sleep during SPT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.